A Phase 4 interventional study of Risperidone and Other atypical antipsychotic drugs in Schizophrenia, Bipolar Disorder and Autistic Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 29 sites in 6 countries. Open to participants aged 8 Years to 16 Years. Per ClinicalTrials.gov, last updated 2012-11-27.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.
Among the 127 studies testing risperidone in Schizophrenia, this one is the 29th largest by enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2009, is one of 63 in phase 4, and was the 77th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 8 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 7 · Phase 3 34 · Phase 4 63
First in 1996; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 123 interventional studies. Of the 106 that completed or were terminated, 30 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 66th largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2009, is one of 47 in phase 4, and was the 130th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing risperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 127 studies testing risperidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events (side effects) associated to these drugs.
This is a study to find out what the effects are of long-term use of atypical antipsychotics (drugs used to treat mental health and some behavior disorders) in children and adolescents on their growth and physical maturity. Atypical antipsychotics are used in the treatment of a wide range of disorders in children and adolescents, such as; schizophrenia, bipolar mania, autistic disorder or other disruptive behavior disorders. This study does not involve using any new medication, but to look into some of the side effects that children and adolescents may experience from taking an atypical antipsychotic. One of the side effects of some atypical antipsychotics is an increased level of "prolactin", a hormone that occurs naturally in the body which can lead to "hyperprolactinemia" a condition in which the pituitary gland produces too much prolactin. In order to further investigate these possible side effects, two groups of children and adolescents (aged 8 to 16) with a diagnosis of schizophrenia, bipolar mania, autistic disorder, or conduct and other disruptive behavior disorders who are or have been recently treated with an atypical antipsychotic will be enrolled; 1 group of children and adolescents will either be currently taking or have recently been treated with risperidone and the second group of children and adolescents will either be currently taking or have recently been treated with an a similar type of atypical antipsychotic therapy. The results will then be compared to see if the age of physical maturation, growth and development differs between the two groups, using data collected during an office visit and previous information available from existing medical records. The patient's growth will be assessed using information on height and weight taken from the medical records at different time points before (up to one year previous) and since they started treatment with antipsychotic therapy. In addition, there will also be one visit to the clinic where the growth and stage of sexual maturity of the patient will be reviewed by both the study doctor and through the patient's own assessment, using a questionnaire and pictures developed specially to assess stages of physical development (so called - Tanner stage). In addition, one blood sample will be taken from each patient to check the levels of prolactin hormone in the blood to see if this differs between treatment groups. Potential patients will be identified through automated databases and/or medical chart review. If, after fully understanding the purpose of this study, the parent, legal guardian and their child agree to participate by signing an informed consent (children to sign an assent form), information (specified below) related to your child's treatment and development will be collected directly from central medical records or from notes kept by your child's doctor for evaluation. The following data will be collected from available medical records: information about the patient's use of antipsychotic drug and prescriptions; previous records of the patient's height, weight, and growth; physical and sexual development (so called, Tanner stage [developmental stage]) if available; results of previous blood tests taken to evaluate the level of the hormone prolactin if available; and, history of any side effects that could be related to increased levels of the hormone prolactin. All the above information will be collected within 1 year before the patient started antipsychotic therapy. The same information (if available) will also be collected following the time that the patient starting taking their atypical antipsychotic medication until the present time. As much information as possible will be collected for this period of time so that a determination of how taking antipsychotic drugs may have influenced the patient's growth can be made. The study doctor will see each patient for a single study visit. This visit will take place at a convenient time approximately one week after informed consent/assent has been obtained. At the clinic visit, the study doctor will do some examinations to check the patient's general health and assess their growth and physical development. These will include: a physical examination (including developmental stage assessment [Tanner stage]), weight and height, vital signs (pulse, respiration rate, temperature and blood pressure), medical history, and the collection of information regarding the occurrence of any side effects thought to be related to the use of atypical antipsychotic medication or related to the hormone prolactin. In addition to being assessed by the study doctor, the patient will be asked to complete the Tanner Stage questionnaire. This will involve the patient reviewing both pictures and written descriptions of children at different stages of physical development. The patient will have to decide which picture/description is most representative of their body. The study doctor will also look at the patient's current use of any other medications. Each patient will participate in the study for about one week. The outcome measures of the study will be to compare Z-scores for height, age at current Tanner stage, and prolactin-related adverse events between patients exposed to risperidone and patients exposed to other atypical antipsychotic drugs. Outcome measures will be collected during the study visit and retrospectively during the time of exposure for up to 2 years prior to the study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Risperidone as per local prescribing practices
Drug: Risperidone
Other atypical antipsychotic drugs as per local prescribing practices
Drug: Other atypical antipsychotic drugs
As per local prescribing practices
As per local prescribing practices
Height (cm) Z-score at Study Visit
Height (cm) measured at the study visit was converted to a Z-score based on the US Center for Disease Control 2000 growth charts for US subjects and European growth charts for ex-US subjects. A z-score indicates how many standard deviations a subject is away from the expected height for the subject's age and gender.
Time frame: One single study visit, approximately one week after informed consent has been obtained
Age (Years) at Current Tanner Stage
Tanner stage is an evaluation of pubertal development with values ranging from 1 (pre-pubertal) to 5 (adult). A standardized, validated tool containing standardized pictures and written descriptions of the stages of pubic hair development, breast development for girls, and genital development for boys was used by physicians to make their assessment.
Time frame: One single study visit, approximately one week after informed consent has been obtained
Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events
Previous potentially prolactin-related adverse events, including hyperprolactinemia, were reviewed and abstracted from participants' medical records. Potentially prolactin-related adverse events include breast symptoms, menstrual disorders, hyperprolactinemia, and prolactinoma.
Time frame: Retrospectively during the time of exposure for up to 2 years prior to the study visit
A total of 244 subjects were assessed for eligibility of whom 230 signed informed consent. Of the 230, 43 were found not to meet inclusion or exclusion criteria, 2 withdrew consent, and 1 was not kept in the study due to a site decision. A total of 184 subjects were included in the analysis.
| Milestone | Risperidone | Other Atypical Antipsychotics |
|---|---|---|
| Started | 133 | 51 |
| Completed | 133 | 51 |
| Not completed | 0 | 0 |
Height (cm) measured at the study visit was converted to a Z-score based on the US Center for Disease Control 2000 growth charts for US subjects and European growth charts for ex-US subjects. A z-score indicates how many standard deviations a subject is away from the expected height for the subject's age and gender.
| z-score | Risperidone | Other Atypical Antipsychotics |
|---|---|---|
| Height (cm) Z-score at Study Visit | 0.40 ± 1.189 | 0.09 ± 1.079 |
Tanner stage is an evaluation of pubertal development with values ranging from 1 (pre-pubertal) to 5 (adult). A standardized, validated tool containing standardized pictures and written descriptions of the stages of pubic hair development, breast development for girls, and genital development for boys was used by physicians to make their assessment.
| years | Risperidone | Other Atypical Antipsychotics |
|---|---|---|
| Tanner Stage 1 | 10.2 ± 1.31 | 10.3 ± 1.78 |
| Tanner Stage 2 | 11.3 ± 1.68 | 11.2 ± 1.73 |
| Tanner Stage 3 | 13.1 ± 2.18 | 12.2 ± 1.21 |
| Tanner Stage 4 | 14.9 ± 1.27 | 15.0 ± 1.46 |
| Tanner Stage 5 | 15.1 ± 0.69 | 15.0 ± 1.82 |
Previous potentially prolactin-related adverse events, including hyperprolactinemia, were reviewed and abstracted from participants' medical records. Potentially prolactin-related adverse events include breast symptoms, menstrual disorders, hyperprolactinemia, and prolactinoma.
| participants | Risperidone | Other Atypical Antipsychotics |
|---|---|---|
| Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events | 7 | 3 |
Collected over Days from signing of informed consent to study visit. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risperidone | — | 0/133 (0%) | 8/133 (6%) |
| Other Atypical Antipsychotics | — | 0/51 (0%) | 3/51 (5.9%) |
| Event | Risperidone | Other Atypical Antipsychotics |
|---|---|---|
| FatigueGeneral disorders | 1/133 | 1/51 |
| Breast painReproductive system and breast disorders | 0/133 | 1/51 |
| Lower respiratory tract infectionInfections and infestations | 0/133 | 1/51 |
| NasopharyngitisInfections and infestations | 0/133 | 1/51 |
| Blood prolactin increasedInvestigations | 1/133 | 0/51 |
| Eye infectionInfections and infestations | 1/133 | 0/51 |
| SedationNervous system disorders | 1/133 | 0/51 |
| HeadacheNervous system disorders | 1/133 | 0/51 |
| Middle insomniaPsychiatric disorders | 1/133 | 0/51 |
| Weight increasedInvestigations | 1/133 | 0/51 |
| Age Continuous(years) | Risperidone | Other Atypical Antipsychotics | Total |
|---|---|---|---|
| Mean | 12 ± 2.5 | 12 ± 2.5 | 12 ± 2.5 |
| Sex: Female, Male(Participants) | Risperidone | Other Atypical Antipsychotics | Total |
|---|---|---|---|
| Female | 16 | 18 | 34 |
| Male | 117 | 33 | 150 |
| Race (NIH/OMB)(Participants) | Risperidone | Other Atypical Antipsychotics | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 12 | 6 | 18 |
| White | 110 | 36 | 146 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 7 | 7 | 14 |
| Region of Enrollment(participants) | Risperidone | Other Atypical Antipsychotics | Total |
|---|---|---|---|
| United States | 59 | 40 | 99 |
| Germany | 41 | 6 | 47 |
| Poland | 19 | 3 | 22 |
| Netherlands | 8 | 0 | 8 |
| Greece | 3 | 2 | 5 |
| Belgium | 3 | 0 | 3 |
The record gives a start of Oct 2009, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risperidone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →